Dexlansoprazole
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB05351 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 26 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | active peptic ulcer disease | KG + DL |
| 2 | gastrojejunal ulcer | KG + DL |
| 3 | peptic ulcer perforation | KG + DL |
| 4 | gastric ulcer (disease) | KG + DL |
| 5 | gastroduodenitis | KG + DL |
| 6 | duodenal obstruction | KG + DL |
| 7 | duodenogastric reflux | KG + DL |
| 8 | duodenal ulcer (disease) | KG + DL |
| 9 | achlorhydria | KG + DL |
| 10 | leather-bottle stomach | KG + DL |
| 11 | hiatus hernia (disease) | KG + DL |
| 12 | gastric dilatation | KG + DL |
| 13 | Dieulafoy lesion | KG + DL |
| 14 | cascade stomach | KG + DL |
| 15 | pylorospasm | KG + DL |
| 16 | gastrin secretion abnormality | KG + DL |
| 17 | multiple endocrine neoplasia | KG + DL |
| 18 | hemorrhagic duodenitis | KG + DL |
| 19 | duodenitis | KG + DL |
| 20 | pancreas disease | KG + DL |
| 21 | Smouldering systemic mastocytosis | KG + DL |
| 22 | eosinophilic esophagitis | KG + DL |
| 23 | lymphoadenopathic mastocytosis with eosinophilia | KG + DL |
| 24 | abnormality of glucagon secretion | KG + DL |
| 25 | Zollinger-Ellison syndrome | KG + DL |
| 26 | intraepithelial neoplasia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.